Kornimate/medical-research-clean huggingface dataset:
natural history of hpv infection in men: the him study

Conditions: Human Papillomavirus

Summary: the purpose of this study is to learn about the natural history of human papillomavirus (hpv) infection in men. the study will also find out what factors are linked to hpv in men including other sexually transmitted diseases (stds). if participants test positive for syphilis, gonorrhea or chlamydia, we are required by law to report the results to the florida department of health. participants will be able to get free medical treatment from the florida department of health for these stds. participants will be given a written report of the results of the std testing.

the study protocol will include a pre-enrollment run-in visit, a baseline visit (enrollment), and 8 additional visits after enrollment scheduled 6 months apart. intervals of every 6 months were chosen to insure that both acquisition and loss of infections may be assessed, as studies in women indicate that median duration of oncogenic infections ranges between 7-9 months. informed consent will occur during the run-in visit. the run-in and follow-up visits will include questionnaire administration, visual inspection of the skin and external genitalia, and the collection of urine, blood, oral cells, and penile skin samples if anogenital lesions are present at any of the clinic visits, they will be sampled as well.

Eligibility criteria:
inclusion criteria: * men between 18 and 70 years of age, living in southern florida, us; sao paulo, brazil; or state of morelos, mexico. * participant has never been told that they have penile or anal cancer or genital warts. * willing to attend scheduled visits every 6 months in the next 4 years. exclusion criteria: * prospective participants with symptoms of any std (excluding hpv) during screening will not be eligible to participate in the study until the std (sexually transmitted disease) infection is gone.

Keywords: hpv papillomavirus infection sexually transmitted disease std
a study evaluating the effects of nebivolol on blood pressure in hypertensive patients

Conditions: Hypertension

Summary: the purpose of this study is to evaluate the effects of various doses of nebivolol in patients with mild to moderate hypertension.

this was a multi-center, randomized, double-blind, parallel group, placebo-controlled study of nebivolol over a range of doses in patients with mild to moderate hypertension. the study consisted of 2 phases: screening/washout/single-blind placebo run-in followed by randomization/double-blind treatment. during the double-blind phase, patients received nebivolol or placebo. patients had 7 scheduled clinical visits during the study.

Eligibility criteria:
inclusion criteria: * an average sitting diastolic blood pressure of greater then or equal to 95 mmhg and less then or equal to 109 mmhg at baseline exclusion criteria: * recent myocardial infarction or stroke * secondary hypertension * contraindications to beta-blocker treatment or discontinuation of current antihypertensive therapy * pregnancy, nursing, or women of child-bearing potential not using appropriate contraception

Keywords: nebivolol hypertension beta-blocker
drainage or not for laparoscopic cholecystetomy

Conditions: Cholecystitis; Cholecystolithiasis; Polyps Gallbladder; Adenomyosis of Gallbladder

Summary: surgeons usually choosing drainage tube for laparoscopic cholecystectomy according to their experiences but not guidelines. the investigators design a rct to evaluate the role of drainage in lc surgery and compare the clinical results between drainage and no drainage.

the investigators design a rct to evaluate the role of drainage in lc surgery and compare the clinical results between drainage and no drainage. compare complications as below betwwen drainage and no drainage groups. 1. vas 2. nause and vomiting 3. infection 4. bleeding 5. bile leakage 6. puncture drainage 7. readmission 8. reoperation 9. hospital stay 10. hospital expense

Eligibility criteria:
inclusion criteria: * age:18-75 years old * indicated and planed to receive laparoscopic cholecystectomy exclusion criteria: * cirrohosis child grading b and c * upper abdominal surgery history * adjustment of surgical name intraoperative
harmonic scalpel vs. electrocautery in breast reduction surgery

Conditions: Hyperplasia

Summary: purpose: the aims of this randomized clinical trial are to assess and compare 3 different outcomes in women undergoing breast reduction surgery using two different surgical devices: the harmonic scalpel and electrocautery. the three metrics are: 1. the time taken to complete the operation 2. drainage volume in the days immediately following surgery, 3. patient pain in the days immediately following surgery.


Eligibility criteria:
inclusion criteria: * patients are eligible for enrollment if they agree to provide informed consent, can read and speak english, are at least 18 years of age, and are in generally good health. exclusion criteria: * under 18 years of age

Keywords: mammaplasty electrocoagulation breast
biometric characteristics of the eye with microcornea/microphthalmia and congenital cataract before and after cataract extraction

Conditions: Congenital Cataract; Microphthalmos; Microcornea

Summary: early cataract surgery in microcornea/microphthalmia eyes is essential to prevent amblyopia and improve visual outcomes, including stereopsis. however, despite recent advances in pediatric cataract microsurgical techniques, this surgery remains challenging owing to several intraoperative difficulties attributable to the crowded anterior segment in these small, soft, and poorly developed eyes with shallow anterior chambers, and poor pupillary dilation. in this study the investigator aim to report on the changes in the anterior segment biometric characteristics after cataract extraction in eyes with microcornea/microphthalmia with congenital cataract.

eyes with congenital cataract have usually small cornea due to developmental delay of the globe. recognition of microcornea/microphthalmia may be important as a potential contributor to the development of aphakic glaucoma after cataract surgery. biometrics characteristics of eyes with m/m before and after removal of the cataractous lens can justify the occurrence of postoperative complications, including glaucoma. aim of the study: to report on the changes in the anterior segment biometric characteristics after cataract extraction in eyes with microcornea/microphthalmia with congenital cataract. methods: the study will be a prospective cohorte. biometry of eligible eyes with congenital cataract in one or both eyes with horizontal cornea diameter less than 11mm and/or axial length less than 2standard deviation for age will be compare to otherwise normal eyes with congenital cataract before and after cataract extraction. the anterior segment biometric characteristics using ultrasound biomicroscopy to measure anterior chamber depth and angle.cataract surgery will be conducted with or without intraocular lens implantation.postoperative follow up will be scheduled at the first week and first month, third and sixth months

Eligibility criteria:
inclusion criteria: 1. children presenting with congenital cataract in one or both eyes and with a horizontal corneal diameter less than 11 mm and/or an axial length less than 2 standard deviations for age of the child, less than 18mm in children under one year and less than 20mm in those less than 1year (cases). 2. children presenting with congenital cataract in one or both eyes with otherwise normal ocular biometric characteristics (controls). exclusion criteria: 1.children presenting with congenital cataract associated with other ocular anomalies other than microcornea/microphthalmia

Keywords: anterior segment biometry cataract surgery aphakia/ pseudophakia
risk factors for thrombosis in immune thrombocytopenia

Conditions: Immune Thrombocytopenia

Summary: immune thrombocytopenia (itp) is a rare autoimmune disease (annual incidence: 3-4/105 inhabitants) leading to an increased risk of spontaneous bleeding. itp is said "primary" when not associated to other systemic disease (lymphoma, systemic autoimmune disease, chronic infectious disease...). first-line treatment is based on corticosteroids. intravenous immunoglobulin (ivig) is added in case of serious bleeding. in about 70% of adult cases, itp becomes persistent or chronic (lasting \>3 months and \>12 months, respectively). second-line treatments are then indicated. among them, thrombopoietin-receptor agonists (tpo-ras), romiplostim and eltrombopag are increasingly used. splenectomy is used as ultimate treatment. paradoxically, the risk of thrombosis is higher in itp patients in comparison with the general population, due to the release of young hyperactive platelets from bone marrow. the incidence of thrombosis in itp patients has been estimated between 0.5 and 3/100 patients-years. however, risk factors for thrombosis in itp are not known, except splenectomy that is used in very few patients now. the role of other itp treatments in thrombosis occurrence has been evoked, particularly for corticosteroids and ivig. tpo-ras have been associated with a risk of thrombosis in clinical trials and pharmacovigilance studies, even in case of low or normal platelet count. however, this risk has not been measured in the real-life practice, adjusted for other risk factors for thrombosis.


Eligibility criteria:
inclusion criteria: * incident primary itp adults exclusion criteria: * secondary as well as prevalent itp patients on july, 30th 2009 are excluded by the algorithm

Keywords: thrombosis
comparative microarray analysis in primary cutaneous malignant melanoma

Conditions: Cutaneous Malignant Melanoma

Summary: perturbations in microrna (mirna) expression profiles has been reported for cutaneous malignant melanoma (cmm). this study will be an exploratory analysis by mirna expression profiling using microarrays.

perturbations in microrna (mirna) expression profiles has been reported for cutaneous malignant melanoma (cmm). with regards to a rapidly growing number of newly discovered mirna sequences, the availability of up-to-date mirna expression profiles for primary cutaneous malignant melanoma (pcmm), cutaneous malignant melanoma metastases (cmmm) and benign melanocytic naevi (bmn) is limited. patients with pcmm, cmmm and bmn are included in the study to perform an exploratory analysis by mirna expression profiling using microarrays. expression levels of mirna candidates will be validated by taqman real-time quantitative polymerase chain reaction (rt-pcr).

Eligibility criteria:
inclusion criteria: * primary cutaneous malignant melanoma * cutaneous malignant melanoma metastases * benign melanocytic naevi exclusion criteria: - other skin cancer than primary cutaneous malignant melanoma
impact of raltegravir on the viral reservoirs

Conditions: HIV Infection

Summary: the objective of the antiretroviral treatment is to inhibit the viral replication, estimated(appreciated) by the measure of the viral plasmatic load(responsibility). in this inhibition of the viral replication usually joins an immune reconstruction \[ 1 \]. nevertheless, a viro-immunological dissociation, i.e. an undetectable viral load(responsibility) and an absence of immune reconstruction, is regularly observed. it is now turned out that an undetectable viral load(responsibility) does not correspond to the total absence of viral replication and that it is possible to detect of the intracellular pro-viral dna . raltegravir ®, because of its mode of action(share) inhibiting the integration of the pro-viral dna in the chromosomes of the infected cells(units) , could decrease the intracellular reservoir of monocyte-macrophages, improve the homeostasis, so optimizing the cooperation lymphocytes t - macrophages. several experimental data suggest that the regression of the abnormalities of cellular interactions, and the rate of apoptose abnormally raised(abnormally brought up) by cells(units) t at the patients in viro-immunological dissociation, could be obtained . this study aims at measuring the impact of raltegravir ® on the viral reservoirs lymphocyte and monocyte, to quantify the expression of the molecules of costimulation, the source(spring) of intercellular interactions lymphocytes - monocytes, and to measure the rate of apoptose of the cells(units) t.

20 patients will be included and followed over a period of 12 months population of the essay criteria of inclusion: patients from 18 years to 60 years hiv + treated(handled): * patients presenting an undetectable viral load(responsibility) for at least 6 months and no more than year, by the use of a tritherapy containing 2 nuc + 1 ip. * patients presenting an immunosuppression "average" with a rate of t cd4 understood between 350 and 500 cells(units) by ml. * patients known for a perfect observance. criteria of not inclusion: * preliminary use of an inhibitor of the integrase * patients presenting an opportunist infection and\\or an evolutionary cancer * patients benefiting from a treatment by il-2, interferon-alpha, steroids or the other medicines known to modify the immunity. * pregnant women

Eligibility criteria:
inclusion criteria: patients from 18 years to 60 years hiv + treated(handled): * patients presenting an undetectable viral load(responsibility) for at least 6 months and no more than year, by the use of a tritherapy containing 2 nuc + 1 ip. * patients presenting an immunosuppression "average" with a rate of t cd4 understood between 350 and 500 cells(units) by ml. * patients known for a perfect observance. * exclusion criteria: preliminary use of an inhibitor of the integrase * patients presenting an opportunist infection and\\or an evolutionary cancer * patients benefiting from a treatment by il-2, interferon-alpha, steroids or the other medicines known to modify the immunity. * pregnant women
elx/tez/iva expanded access program for cystic fibrosis (cf) patients with at least one f508del mutation

Conditions: Cystic Fibrosis

Summary: the purpose of this program is to provide elexacaftor/tezacaftor/ivacaftor (elx/tez/iva) to cf patients in critical need who are 6 to 11 years of age with at least one f508del mutation in response to unsolicited physician requests.


Eligibility criteria:
key inclusion criteria: * patients with confirmed diagnosis of cf who have an f/any genotype * prior treatment for at least 6 months with an approved alternative cftr modulator (if the patient is eligible for such treatment) * patients with percent predicted forced expiratory volume in 1 second (ppfev1) \<40 for a minimum of 60 consecutive days before the date of completion of the request form key exclusion criteria: * patients with severe hepatic impairment other protocol-defined inclusion/exclusion criteria may apply
estimation of the tissue and serum levels of interleukin (il) -35 in mycosis fungoides: a case control study

Conditions: Mycosis Fungoides

Summary: tissue and serum samples from 20 mf patients and 20 normal healthy controls will be subjected for biochemical assessments by elisa (enzyme- linked immune-sorbent assay) for assessing the level of il35.

tissue and serum samples from 20 mf patients and 20 normal healthy controls will be subjected for biochemical assessments by elisa (enzyme- linked immune-sorbent assay) for assessing the level of il35

Eligibility criteria:
inclusion criteria: * patients with mycosis fungoides. both genders. age group ≥ 18 years old. exclusion criteria: * patients with any other skin diseases. patients who received treatments for mycosis fungoides in the past three months. subjects with history of solid or hematological malignancy as leukemia
placebo and active controlled study to assess efficacy and tolerability of aspirin plus pseudoephedrine

Conditions: Common Cold; Pharyngitis

Summary: the purpose of this study is compare efficacy and tolerability of a fixed combination, containing 500 mg acetylsalicylic acid and 30 mg pseudoephedrine, in comparison to its single components in patients with sore throat and nasal congestion.


Eligibility criteria:
inclusion criteria:- male and female subjects between 18 and 65 years of age.- onset of cold symptoms within 96 hours (4 days) before study participation.- current complaint of at least moderate sore throat at baseline- current complaint of at least moderate nc at baseline- history of other symptoms associated with urti during the last 4 days before study participation.- other findings of urti, confirmed on the physical examination.- agreement to comply with the study requirements.- written informed consent prior to enrollment in the study exclusion criteria:- pregnant or lactating females.- uncontrolled chronic diseases.- history of hypersensitivity (allergic reaction) to asa, any other nonsteroidal anti-inflammatory drugs (nsaids), or pse.- any disease which significantly compromises breathing or interferes with the subjects assessment of sore throat.- history of or active peptic ulcer.- severe impaired hepatic function.- severe impaired renal function.- simultaneous intake of monoamine oxidase inhibitors.- use of menthol containing tissues within 2 hours before first intake of study drug.- intake of any menthol containing product within 4 hours before first intake of study drug.- use of any local or systemic short acting cough and cold preparations within 6 hours before first intake of study drug.- use of any local or systemic long acting cough and cold preparations within 12 hours before first intake of study drug.- intake of any analgesic within 12 hours before first intake of study drug.- intake or requirement of any prescription medication for the treatment of the current acute respiratory tract infection.- current or previous intake of anticoagulants, corticoids, nsaids, methotrexate, or lithium.- participation in another clinical trial within the last 30 days.

Keywords: sore throat upper respiratory tract infections nasal congestion
dysarthria management for minor groups

Conditions: Parkinson Disease; Dysarthria

Summary: this study develops and conduct a small-scale clinical trial study in which the linguistic and cultural diversity of the participants is considered. speech therapy and counseling services are provided to both patients with parkinson\&#39;s disease and their caregivers.

attention has been increasingly paid to the "culturally and linguistically diverse (cld)" communities which typically include dialectal users of english, monolingual and multilingual speakers of minority languages, and bilingual speakers of english and a minority language. however, among these, monolingual speakers of minority languages living in the us have been nearly excluded from dysarthria management. most of these are first-generation immigrants who are well documented to have limited access to financial and medical services and have poorer health outcomes including communication difficulties. this creates critical health disparities in the field of communication rehabilitation. this study will (1) examine effects of speech therapy on pd patients' speech acoustics and intelligibility, (2) examine effects of the intervention program on communication participation and well-being of both pd patients and their families. our primary outcome measures, speech intelligibility and acoustic measures, are hypothesized to show improvements. acoustic predictors of speech intelligibility are expected to include acoustic vowel space and voice onset time. these hypotheses are based on literature reporting (1) positive changes in speech function after intensive treatment programs focusing on vocal effort and hyperarticulation and (2) language-specific contributors to speech intelligibility in pd. our secondary outcome measures include (1) communication participation and (2) well-being measures which will be obtained from both pd patients and family members. based on previous research, the measures are hypothesized to show improved communication participation and well-being in both pd patients and their families following therapy.

Eligibility criteria:
inclusion criteria: * medical diagnosis of pd * no history of other neurological disease * native speaker of korean * age between 25 and 85 * diagnosis of dysarthria secondary to pd from an slp * self-reported typical hearing * access to high-speed internet for therapy sessions exclusion criteria: * a score of 23 or below on the korean montreal cognitive assessment * evidence of voice-speech disorders not-related to pd * received speech therapy for pd-related problems in the past one year * have no family members to participate in the project.

Keywords: speech mental health diversity
chlorthalidone compared to hydrochlorothiazide on endothelial function

Conditions: Hypertension

Summary: chlorthalidone will result in improved endothelial function compared to hydrochlorothiazide as measured by flow mediated vasodilatation.

this is a randomized, double-blind, crossover study to evaluate chlorthalidone and hydrochlorothiazide and their effects on endothelial function in hypertensive patients. subjects will receive chlorthalidone 12.5 mg, hydrochlorothiazide 25 mg, and placebo each for 4 weeks with a 1 week washout between study periods. sequence of study drugs will be randomized. flow mediated vasodilatation will be measured at baseline and after each treatment period.

Eligibility criteria:
inclusion criteria: * age 19 or older * diagnosis of hypertension * current blood pressure \> 120/80 mm hg exclusion criteria: * use of a thiazide-type diuretic within the last 1 month * known allergy to any study medications * history of gout or hyperuricemia * scr \>/= 1.8 mg/dl or crcl \< 25 ml/min * pregnancy or breastfeeding or planning to become pregnant during study period * dementia or cognitive impairment * hypokalemia * acute coronary syndrome or stroke within 6 months * current use of sildenafil, tadalafil, or vardenafil

Keywords: hypertension endothelial dysfunction